thorien said:
"Combining GLP-1 drugs could come with risks beyond what we currently know. At therapeutic doses, these medications are made to fully activate the GLP-1 receptor, so using them together for stronger appetite suppression might be unsafe."
This worries me somewhat, since it looks like a lot of people have begun following this kind of protocol. I suppose the dose matters too? More research would certainly help here.
One correction to the quote above: GLP-1 agonists don't merely switch the receptors on fully, they drive them far past anything physiological, several orders of magnitude beyond what endogenous GLP-1 achieves, and the effect persists for a week where natural GLP-1 clears within minutes. The standard maximum doses of every GLP-1 drug sit close to the ceiling of what the receptors can do at all, which explains why pushing the dose higher often buys you no further weight loss.
I do agree that for most combinations the risks simply aren't mapped, and there's no substantial evidence behind stacking weight-loss peptides at all. Take the big cagrisema trial: the combination beat either agent alone on weight loss, but it came with a fairly high rate of gastrointestinal side effects and, to the sponsor's disappointment, not a great deal of extra weight loss. What it did not produce was any unexpected serious harm.
Then there are the trials of much higher semaglutide doses, 7.2mg and 16 mg. Those improved weight loss too, again by less than the company hoped, and they carried quite high rates of gastrointestinal side effects plus some sensory skin effects at the 10% rate you normally associate with retatrutide and almost never see on low-dose semaglutide.
So on the available evidence, high-dose GLP-1 therapy isn't unsafe, it's just well into diminishing returns: a little extra weight loss bought with extra side effects. And the only cagrilintide combination anyone has actually studied was with semaglutide — not the pairing most people on grey peptides would choose, but the obvious one when the same company owns both, and Lilly owns reta and tirz besides.
Extrapolating from that, judging cagrilintide plus tirz or reta as fairly unlikely to throw up serious unexpected adverse effects is not unreasonable — though it is certainly not proven safe either.
The ongoing high-dose tirzepatide trial has released nothing at all, not even the doses being tested.
My own view is that severe obesity does very severe damage to physical, social and mental health, and that the added cardiovascular risk from the weight alone is almost certainly an order of magnitude bigger than any plausible long-term harm from combining sensible doses of these drugs, or from running tirz or reta somewhat above the usual dose. Higher sema doses have been studied and remain a poor pick, since 15mg of tirz or 12 of reta is both more effective and far better tolerated than 16mg of semaglutide.
Semaglutide and tirzepatide — though not yet retatrutide — have both been shown to cut overall mortality in high-risk groups, in diabetics and in people with cardiovascular disease. That argues against any severe adverse effect still sitting undiscovered. Both are also proven to lower the risk of a very long list of conditions: diabetes, hypertension, high lipids, a number of obesity-linked cancers, heart attacks, strokes, alcoholism, other drug-use disorders and more. So it is extremely unlikely that some long-term harm will eventually turn up that outweighs all of that, even at higher doses or in combination. The companies are plainly interested, and further studies will come.
One study that still needs doing is whether higher doses or combinations help the people who respond poorly, or substantially less than average, to these drugs in the first place.
Where severe obesity is being managed, I think taking on the currently unknown risks of higher doses or combinations is reasonable. That is far less certain for someone merely overweight, whose health risk from the extra weight is much milder. Those people usually won't need higher doses or combinations anyway.
